Background: This study aimed to (i) assess the prevalence of exposure to environmental tobacco smoke (ETS) at homes, (ii) assess the prevalence of atopic dermatitis and (iii) evaluate the association between ETS exposure and atopic dermatitis status among adolescents. Methods: During October 2015, a cross-sectional study design was implemented using a self-administered, modified version of the ISAAC (International Study of Asthma and Allergies in Childhood) questionnaire among students enrolled in nine high schools of one of the six governorates of Kuwait. Prevalence of ETS exposure at home (1 or more smokers at home vs. none) and atopic dermatitis were computed. A multivariable log-binomial regression model was used to evaluate the adjusted association between ETS exposure and atopic dermatitis. Results: Of 800 invited students, 746 (93.3%) participated, of whom 74.8% were Kuwaiti and 50.1% were female with a mean (SD) age of 16.8 (0.68) years. Prevalence of ETS exposure at home was 54%. Prevalence of atopic dermatitis was 14.9%. A final multivariable log-binomial regression model showed that compared with the adolescents free from atopic dermatitis, adolescents with atopic dermatitis were significantly more likely to have had ETS exposure at home (adjusted prevalence ratio = 1.49; 95% CI: 1.03–2.14; p = 0.034) or tended to be female (adjusted prevalence ratio = 1.42; 95% CI: 0.99–2.03; p = 0.054). Conclusions: A high prevalence of ETS exposure at home among adolescents was recorded. ETS exposure and female gender were significantly associated with atopic dermatitis status. Intervention fostering voluntary adoption of a smoke-free home rule may help protect the adolescents against ETS exposure and alleviate the menace of associated morbidity.

1.
US-EPA: Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. Washington, US-EPA, 1992.
2.
Kramer U, Lemmen CH, Behrendt H, Link E, Schafer T, Gostomzyk J, Scherer G, Ring J: The effect of environmental tobacco smoke on atopic dermatitis and allergic sensitization in children. Br J Dermatol 2004; 150: 111–118.
3.
Samet JM, Wang SS: Environmental tobacco smoke; in Spengler JD, Samet JM, McCarthy JF (eds): Indoor Air Quality Handbook. New York, McGraw-Hill, 2000.
4.
WHO: Tobacco Fact Sheet, 2015.
5.
Anderson HR, Cook DG: Passive smoking and sudden infant death syndrome: review of the epidemiological evidence. Thorax 1997; 52: 1003–1009.
6.
Feleszko W, Ruszczynski M, Jaworska J, Strze-lak A, Zalewski BM, Kulus M: Environmental tobacco smoke exposure and risk of allergic sensitisation in children: a systematic review and meta-analysis. Arch Dis Child 2014; 99: 985–992.
7.
Cheraghi M, Salvi S: Environmental tobacco smoke (ETS) and respiratory health in children. Eur J Pediatr 2009; 168: 897–905.
8.
Hwang S-H, Hwang JH, Moon JS, Lee D-H: Environmental tobacco smoke and children’s health. Korean J Pediatr 2012; 55: 35–41.
9.
Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A; ISAAC Phase Three Study Group: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 2013; 41: 73–85.
10.
Mitchell EA, Beasley R, Keil U, Montefort S, Odhiambo J: The association between tobacco and the risk of asthma, rhinoconjunctivitis and atopic dermatitis in children and adolescents: analyses from phase three of the ISAAC programme. Thorax 2012; 67: 941–949.
11.
Owayed A, Behbehani N, Al-Momen J: Changing prevalence of asthma and allergic diseases among Kuwaiti children. An ISAAC study (phase III). Med Princ Pract 2008; 17: 284–289.
12.
Ziyab AH: Prevalence and risk factors of asthma, rhinitis, and atopic dermatitis and their multimorbidity among young adults in Kuwait: a cross-sectional study. Biomed Res Int 2017; 2017: 2184193.
13.
Khalaf M: Smoking cessation practices in Kuwaiti general dental clinics. Med Princ Prac 2013; 22: 576–582.
14.
Zhang X, Martinez-Donate AP, Cook J, Piper ME, Berg K, Jones NR: Battling tobacco use at home: an analysis of smoke-free home rules among US veterans from 2001 to 2011. Am J Publ Health 2014; 104(suppl 4):S572–S579.
15.
Al-Sahab B, Atoui M, Musharrafieh U, Zaitoun F, Ramadan F, Tamim H: Epidemiology of atopic dermatitis among Lebanese adolescents. Int J Publ Health 2008; 53: 260–267.
16.
Shirinde J, Wichmann J, Voyi K: Environmental tobacco smoke and the risk of atopic dermatitis symptoms among school children in South Africa: a cross-sectional study. BMJ Open 2015; 5:e008234.
17.
Song N, Shamssain M, Zhang J, Wu J, Fu C, Hao S, Guan J, Yan X: Prevalence, severity and risk factors of asthma, rhinitis and atopic dermatitis in a large group of Chinese schoolchildren. J Asthma 2014; 51: 232–242.
18.
Holt PG: Immune and inflammatory function in cigarette smokers. Thorax 1987; 42: 241–249.
19.
Meliska CJ, Stunkard ME, Gilbert DG, Jensen RA, Martinko JM: Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol 1995; 95: 901–910.
20.
Boguniewicz M, Leung DY: Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010; 125: 4–13; quiz 14–15.
21.
Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood atopic dermatitis. Int J Clin Pract 2006; 60: 984–992.
22.
Osman M, Hansell AL, Simpson CR, Hollowell J, Helms PJ: Gender-specific presentations for asthma, allergic rhinitis and atopic dermatitis in primary care. Primary Care Respir J 2007; 16: 28–35.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.